Health and Healthcare
Stemline Therapeutics Files for IPO (STML)
Published:
Last Updated:
Stemline Therapeutics, Inc. has just filed its paperwork with the Securities and Exchange Commission that will allow it to conduct an initial public offering. The company will list is shares under the ticker “STML” on NASDAQ. The company hired Oppenheimer & Co. and JMP Securities to lead its initial public offering.
The filing noted in its own description area:
We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk. We believe that we are developing the most clinically advanced pipeline of anti-CSC therapeutics and that we hold a broad portfolio of CSC-focused intellectual property, establishing us as a leader in the CSC field.
No financial terms were disclosed other than this offering will be for up to $50 million. The company has three uses for the proceeds in the offering:
JON C. OGG
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.